Statistical Analysis Plan

A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Subjects with Relapsed or Refractory Peripheral T-cell Lymphoma

Protocol Number: FOT12-CN-301
Version: V2.0
Date: February 07, 2018
Sponsor: Mundipharma (China) Pharmaceutical Co., Ltd
Sponsor Address: Room 1808 Tower D CITC, 6A Jianguomen Wai Avenue, Beijing 100022, China
National Principal Investigator: Jun Zhu
Leading Investigational Institute: Beijing Cancer Hospital
CRO: Hangzhou Tigermed Consulting Co., Ltd
Confidentiality Statement

The information contained in this Statistical Analysis Plan (SAP) is confidential and the information contained within it may not be reproduced or otherwise disseminated without the approval of Mundipharma (China) Pharmaceutical Co., Ltd or its subsidiaries.
TABLE OF CONTENTS

1. INTRODUCTION ........................................................................................ 8

2. OBJECTIVES AND PARAMETERS ................................................................ 8
   2.1. Objectives .......................................................................................... 8
       2.1.1. Aim of the study ........................................................................ 8
       2.1.2. Primary Objective .................................................................... 8
       2.1.3. Secondary Objectives ................................................................. 8
   2.2. Parameters .......................................................................................... 8
       2.2.1. Primary Efficacy Variable .......................................................... 8
       2.2.2. Secondary Efficacy Variables .................................................... 9
       2.2.3. Safety Variables ........................................................................ 9
       2.2.4. Pharmacokinetic Measurements .............................................. 9

3. STUDY DESIGN ........................................................................................ 9
   3.1. Summary of Study Design .................................................................. 9
   3.2. Sample Size Rationale ....................................................................... 11
   3.3. Assessment and Procedure .................................................................. 11
       3.3.1. Schedule Overview ................................................................. 11

4. ANALYSIS POPULATIONS ........................................................................ 14

5. GENERAL CONSIDERATIONS FOR DATA ANALYSES AND HANDLING ......................................................................................... 14
   5.1. General Considerations for Data Analyses ........................................ 14
   5.2. Missing Data .................................................................................... 15
   5.3. Baseline Definition ........................................................................... 15
   5.4. Response Assessment Date ................................................................ 16
   5.5. Best Response to Prior Treatment of PTCL .................................... 16
   5.6. Reference Code ............................................................................... 16

6. STATISTICAL METHODS .......................................................................... 17
   6.1. Disposition of Subjects ..................................................................... 17
   6.2. Demographic and Baseline Disease Characteristics .......................... 17
   6.3. Protocol Deviations .......................................................................... 18
   6.4. Medical/Surgical History (Other than PTCL) .................................... 18
   6.5. Concomitant Medication ................................................................. 18
   6.6. Exposure .......................................................................................... 18
       6.6.1. IMP Analyses ........................................................................... 18
       6.6.2. Vitamin Supplementation Analyses ........................................ 19
   6.7. Safety Analyses ............................................................................... 19
       6.7.1. Adverse Events (AEs) and Serious Adverse Events (SAEs) .......... 19
       6.7.2. Laboratory Assessment .............................................................. 20
       6.7.3. Vital Signs ............................................................................... 22
       6.7.4. ECG ....................................................................................... 23
       6.7.5. Other Tests .............................................................................. 23
   6.8. Efficacy Analyses ............................................................................. 23
       6.8.1. Primary Efficacy Variable ......................................................... 23
       6.8.2. Secondary Efficacy Variables ................................................... 23
6.8.3. Discordance between Independent Central Review and Investigator Assessment .................................................. 25

6.9. Subgroup Analyses .................................................................................................................. 26

6.10. Pharmacokinetic Analyses .................................................................................................. 26
   6.10.1. Plasma Concentration ...................................................................................................... 27
   6.10.2. Pharmacokinetic Parameters .......................................................................................... 27

7. ATTACHMENTS .......................................................................................................................... 29
LIST OF ABBREVIATIONS

AE        adverse event
ATC       Anatomical-Therapeutic-Chemical
AUC       area under the curve
BMI       body mass index
BOR       best overall response
BSA       body surface area
CI        confidence interval
CLss      steady state clearance
Cmax      maximum observed concentration
CNAP      chest, neck, abdomen, pelvis
CR        complete response
CRF       Case Report Form
CRu       complete response unconfirmed
CSR       Clinical Study Report
CT        computed tomography
CTCAE     Common Toxicity Criteria for Adverse Events
CV        coefficient of variation
DOR       Duration of Response
DP        decimal place
EBV       epstein-barr virus
ECG       electrocardiogram
ECOG      Eastern Cooperative Oncology Group
EDR       early discrepancy rate
IDMC      Independent Data Monitoring Committee
IM        intramuscular
IMP       Investigational Medicinal Product
IV        intravenous
LDH       lactic dehydrogenase
LDR       late discrepancy rate
LLT       Lowest Level Term
MedDRA    Medical Dictionary for Regulatory Activities
ORR       objective response rate
OS        Overall Survival
PD        progressive disease
PFS       Progression-Free Survival
PK        pharmacokinetic(s)
PPP       Per Protocol Population
PR        partial response
PT        Preferred Term
PTCL      peripheral T-cell lymphoma
SAE       serious adverse event
SAP       Statistical Analysis Plan
SE        standard error
SD        standard deviation
SOC       System Organ Class
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAE</td>
<td>treatment emergent adverse event</td>
</tr>
<tr>
<td>Tmax</td>
<td>time of Cmax observation</td>
</tr>
<tr>
<td>t1/2Z</td>
<td>terminal phase half-life</td>
</tr>
<tr>
<td>TTR</td>
<td>Time to Response</td>
</tr>
<tr>
<td>Vdss</td>
<td>steady state volume of distribution</td>
</tr>
</tbody>
</table>
1. **INTRODUCTION**

The analyses described in this document will be included in a Clinical Study Report (CSR) to support a regulatory submission. This Statistical Analysis Plan (SAP) describes all planned analyses that will be conducted and presented for FOT12-CN-301 study and is based upon Section 14 (Statistical Analysis) of the protocol version 1.0 dated April 3, 2015.

The primary analysis will be performed based on a data cut-off date defined after all subjects have been treated for 5 cycles. The final analysis will be performed based on all the subjects complete the study.

2. **OBJECTIVES AND PARAMETERS**

2.1. **Objectives**

2.1.1. **Aim of the study**

The aim of the study is to confirm the efficacy and safety of pralatrexate for the treatment of Relapsed or Refractory peripheral T-cell lymphoma (PTCL) in Chinese population.

2.1.2. **Primary Objective**

The primary objective of this study is to confirm the objective response rate (ORR) among Chinese subjects with relapsed or refractory PTCL treated with pralatrexate together with concurrent vitamin B12 and folic acid supplementation.

2.1.3. **Secondary Objectives**

- To evaluate further efficacy parameters (Duration of Response; Time to Response; Progression-Free Survival; Overall Survival) among Chinese subjects with relapsed or refractory PTCL treated with pralatrexate together with concurrent vitamin B12 and folic acid supplementation
- To evaluate the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to Chinese subjects with relapsed or refractory PTCL
- To determine the pharmacokinetic (PK) profile of pralatrexate among Chinese subjects with PTCL when administered with vitamin B12 and folic acid supplementation

2.2. **Parameters**

2.2.1. **Primary Efficacy Variable**

Objective response rate by International Working Criteria and per central review.
2.2.2. Secondary Efficacy Variables

- Duration of Response (DOR)
- Time to Response (TTR)
- Progression-Free Survival (PFS)
- Overall Survival (OS)

2.2.3. Safety Variables

- Treatment emergent AEs
- Physical examinations
- Clinical laboratory values

2.2.4. Pharmacokinetic Measurements

Pharmacokinetic evaluations will be performed. The PK profile of R-pralatrexate and S-pralatrexate will be determined in 15 subjects at pre-selected sites.

Standard PK parameters will be determined for both enantiomers in plasma (area under the curve [AUC], steady state volume of distribution [Vdss], steady state clearance [CLss], maximum observed concentration [Cmax], time of Cmax observation [tmax] and terminal phase half-life [t1/2Z]). Accumulation in exposure at steady state will also be reported, such as the ratio of AUC [ARAUC] and Cmax [ARCmax]. Collection of plasma to determine the full PK profile will be performed in 15 subjects at pre-selected sites.

3. STUDY DESIGN

3.1. Summary of Study Design

This is a single arm, open-label, multi-center study designed to evaluate the efficacy and safety of pralatrexate in Chinese subjects when administered concurrently with vitamin B12 and folic acid supplementation to subjects with relapsed or refractory PTCL.

This study includes 3 phases: Screening, Treatment (pralatrexate) and Follow-up phases.

Screening Phase:

The screening phase will be of up to 28 days duration (depending on availability of lab results). All potential study subjects will be screened and determined of the eligibility prior to enrolment. The eligible subjects will begin to receive vitamin supplementation at screening phase.

Unless otherwise specified, the protocol defined procedures and evaluations (See Table 1. Schedule of Visits and Procedures) will be performed within 28 days prior to the projected start of pralatrexate administration (cycle 1, dose 1).

Treatment (pralatrexate) Phase:
The start of study treatment is defined as the initiation of pralatrexate treatment. Vitamin supplementation will be initiated at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Once the patient is on-study, the dosing of vitamin supplementation must adhere to the schedule defined by the protocol.

Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even numbered subsequent cycle (i.e. prior to cycles 6, 8, etc). Although radiological response assessments have been scheduled every 14 weeks, unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.

Treatment with pralatrexate will continue until 24 months of administration, or until documented disease progression; unacceptable adverse event(s) indicating intolerance of the lowest study dose allowed (20 mg/m2/week); omission of 3 sequential doses of pralatrexate due to a treatment-related AE; 3-week lapse between pralatrexate doses; development of an AE, intercurrent illness, condition, or procedural complication that may interfere with the subject’s participation; investigator’s decision to withdraw the subject; subject withdraws consent; pregnancy of the subject; noncompliance with trial treatment or procedure requirements; or administrative reasons.

**Follow-up phase:**

All patients who received at least 1 dose of pralatrexate are to attend the Safety Follow-up Visit [30 (± 5) days after the last dose of pralatrexate] and the protocol defined procedures and evaluations will be performed.

After the Safety Follow-up Visit, Routine Follow-up Visits will be based on standard clinical care. All patients who received at least 1 dose of pralatrexate are to attend Routine Follow-up Visits, which will occur every 3 months (± 2 weeks) for determination of progression of disease, subsequent treatment initiation for T-cell lymphoma and survival after the Safety Follow-up Visit for a total duration of 24 months after the last dose of pralatrexate. The protocol-defined procedures/evaluations should be performed at each Routine Follow-up Visit.

Figure 1 Study diagram
3.2. Sample Size Rationale

The primary objective is to demonstrate that the response rate in the Chinese population is greater than \( \geq 15\% \). Assuming a true response rate of 29\%, a sample size of 68 will provide 80% power to demonstrate a response rate of greater than 15\% using a two-sided test at 5% significance level.

3.3. Assessment and Procedure

3.3.1. Schedule Overview

Table 1 presents the schedule of visits and procedures/CRF module
Table 1 Schedule of Visits and Procedures/CRF Modules

<table>
<thead>
<tr>
<th>Visit</th>
<th>CYCLE 1</th>
<th>SUBSEQUENT CYCLES</th>
<th>FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>28 days Prior to Prolutrexan Dose 1</td>
<td>10 Days Prior to Prolutrexan Dose 1</td>
<td>Cycle 1, Dose 1</td>
</tr>
<tr>
<td>Eligibility Criteria/Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical/Surgical History</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Document Histopathology</td>
<td>x(^1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central pathology review(^2)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unilateral bone marrow biopsy and aspirate</td>
<td>x(^3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT of Chest, Neck, Abdomen, Pelvis (CNAP)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Imaging of disease site other than CNAP(^4)</td>
<td>x(^4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical photography with ruler measurement of cutaneous lesions(^4)</td>
<td>x(^4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Record Prior Treatment and Response for PTCL</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Record Medications</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Record Baseline Symptoms</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Record AEs/AE attribution</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Record ECOG Performance Status</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Examination</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Record Height in cm</td>
<td>x(^10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Record Weight in kg</td>
<td>x(^10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calculate EDA</td>
<td>x(^10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin B12 Administration</td>
<td>x(^11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follic Acid Administration</td>
<td>x(^12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitmic Acid Patted Diary Review</td>
<td>x(^11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolutrexan administration</td>
<td>x(^13)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-Lead ECG</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit</td>
<td>CYCLE 1</td>
<td>SUBSEQUENT CYCLES</td>
<td>FOLLOW-UP</td>
</tr>
<tr>
<td>---------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>28 days Prior to Proliferate Dose 1</td>
<td>10 Days Prior to Proliferate Dose 1 though Cycle 1, Dose 1</td>
<td>Weeks 2-8 Within 7 Days Prior to Projected Dose 1</td>
</tr>
<tr>
<td></td>
<td>Cycle 1, Dose 1</td>
<td>24, 48, 72 Hours post-end proliferation</td>
<td>Dose 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Weeks 2-6 Early Study Termination Visit</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Safety FU Visit</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Routine FU</td>
</tr>
<tr>
<td>Hematology</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pregnancy Test (Urine or serum β-hCG)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood for proliferation PK</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Record Subsequent Treatment for T-cell Lymphoma</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Record Date of Death</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Foot notes:
1) Include histopathology from original diagnosis of T-cell lymphoma and/or from tumor biopsy in relapse setting.
2) EBV will be tested by the central pathology review laboratory with the submitted slides.
3) Within 28 days of proliferation dose 1.
4) Perform if applicable to patient.
5) Evaluation of response must be performed within 7 days prior to the projected first dose of the cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (i.e., prior to cycles 6, 8, etc).
6) The procedures outlined will be conducted, if a patient withdraws informed consent and refuses to attend the Safety Follow-up Visit and Routine Follow-up Visits. If possible, the procedures will be performed at the time the patient withdraws consent.
7) All subjects who received at least 1 dose of proliferate are to attend the safety follow-up visit 30 (± 5) days after the last dose of proliferation.
8) Only until subsequent therapy has started.
9) Cycle 1, week 3 only.
10) May be done up to 3 days prior to cycle 1, dose 1.
11) Vitamin B12, 1 mg IM q 8-10 weeks, initiated as described.
12) Folic acid, 1.2 mg, by mouth daily, initiated as described.
13) Administer proliferation IV push over 3-5 minutes.
14) Laboratory tests will be conducted in local laboratory, central laboratory, and laboratory for PK test respectively.
15) Chemistry labs (including LDH) must be completed within 3 days prior to cycle 1, dose 1. Hematology must be completed within 1 day prior to dosing on cycle 1, dose 1 and platelet count must have remained ≥ 100,000/μL (or 100 x 10^9/L) to proceed with proliferation dosing.
16) Collect LDH prior to first dose of cycle 2-4 and then prior to every even-numbered subsequent cycles (i.e., prior to cycles 6, 8, etc.).
17) Collect blood for chemistry panel prior to the fourth dose of each cycle.
18) Serum β-human chorionic gonadotropin (β-hCG) pregnancy test for women who are not postmenopausal or surgically sterile will be performed within 14 days prior to cycle 1, dose 1. A urine pregnancy test should also be performed within 72 hours prior to first dose of each treatment cycles.
19) Collection of plasma to determine the full PK profile will be performed in 15 subjects at pre-selected sites. Cycle 1, week 1, 6: Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 16, 24, 48, and 72 hours post-end injection. Cycle 1, week 2–5: Pre-injection.
4. ANALYSIS POPULATIONS

Enrolled Population
The enrolled population is defined as all subjects who signed informed consent.

Safety Population
The safety population is defined as all subjects who receive at least one dose of IMP.

Per Protocol Population (PPP)
The Per Protocol Population is defined as all subjects in the safety population who fulfil the following criteria:

1) The absence of any major protocol deviations
2) The completion of a minimal 3 doses of exposure to the treatment regimen of one treatment cycle, except discontinuation due to toxicity and disease progression

All major protocol deviations will be agreed at the data review meeting prior to database lock.

Pharmacokinetic Population
The overall PK population is defined as all subjects who receive at least one dose of IMP and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of >5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.

5. GENERAL CONSIDERATIONS FOR DATA ANALYSES AND HANDLING

5.1. General Considerations for Data Analyses

In general, continuous data will be summarized using the following descriptive statistics: n, mean, standard deviation, median, minimum and maximum. The decimal places will be defined as table 2.

Table 2 decimal places for descriptive statistics

<table>
<thead>
<tr>
<th>Label</th>
<th>No. of decimal places (dp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Always present to 0 dp</td>
</tr>
<tr>
<td>Mean</td>
<td>1 dp more than raw data</td>
</tr>
<tr>
<td>Median</td>
<td>Same as raw data if the number of data points is odd. 1 dp more than raw data if the number of data points is even.</td>
</tr>
<tr>
<td>SD</td>
<td>2 dp more than raw data</td>
</tr>
<tr>
<td>Min</td>
<td>Same as raw data</td>
</tr>
<tr>
<td>Max</td>
<td>Same as raw data</td>
</tr>
</tbody>
</table>

Categorical data will be summarized as the number and percentage of subjects in each category.

All unscheduled records will be included in the corresponding listings but not included in the summary analyses.
All data processing, summarization and analyses will be performed using Version 9.1.3 (or later) of the SAS® statistical software package (Windows OS).

5.2. Missing Data

In general, all available data will be included in the analyses and will be summarized as far as possible. Unless otherwise specified there will be no substitution of missing data, i.e. missing data will not be replaced but will be handled as 'missing' in the statistical evaluation.

For plasma concentration data, all values below the quantifiable limit will be set to 0 for descriptive summary statistics.

For partial dates, no imputation rule will be derived for listings. For tables, when calculating duration of PTCL, if initial diagnosis date of PTCL does not have complete information of day, month, and year, it will be imputed with the criteria as

Imputation for incomplete start dates:

- If year, month and day are missing then use the minimum of the subject's first visit date or the consent date.
  - If month and day are missing then use January 1.
  - If only day is missing, then use 1 for the first day of the month.

Imputation for incomplete end dates:

- If year, month, and day are missing then use the subject's last visit date.
  - If month and day are missing then use December 31.
  - If only day is missing, then use the last day of the month.
  - Do not expand the record past the subject's last visit.

When defining TEAE, if any AEs have partial start date, it will be imputed with the criteria as

- If year, month and day are missing then use the minimum of the subject's first visit date or the consent date.
  - If month and day are missing, first compare with year of first dose. If they are same then use first dose date else use January 1.
  - If only day is missing, first compare with year and month of first dose. If they are same then use first dose date else use 1 for the first day of the month.

No partial dates will be imputed for efficacy endpoint calculation.

5.3. Baseline Definition

Baseline is defined as the last non missing value before first intake of IMP in cycle 1.
5.4. Response Assessment Date

For the efficacy analysis, investigator response assessment date is calculated as

- If the response is PD, then choose the earliest dates among target, non-target and new lesion measurement per cycle.

- If the response is non PD, then choose the latest dates among target and non-target lesion measurement per cycle.

5.5. Best Response to Prior Treatment of PTCL

- If the subject has any responses of CR, CRu, PR, SD, PD or NA, the best response should be CR > CRu > PR > SD > NA > PD.

5.6. Reference Code

- Exact binomial test: Proportion and CI

  ods output BinomialProp = xx1  BinomialCLs = xx2;
  proc freq data=xxx;
    tables response / binomial(exact);
    weight Count;
  run;

- Kaplan-Meier method: Quartile and corresponding CI, Product-Limit Survival Estimates

  proc lifetest data = xxx;
    time aval*CNSR(1);
    ods output censoredSummary = xx1
       quartiles = xx2
       ProductLimitEstimates = xx3;
    survival out = xx4 confband=ALL bandmin=100 bandmax=500 maxtime=600;
  run;

- CI for Geometric Mean

First log-transformed for each value, i.e. logaval = log(aval).

  proc means data = xxx n mean std median max min noprint clm
  alpha=0.05;
  var logaval;
  output out = xx1 LCLM=lclm uclm=uclm;
  run;

Then the transformed back lower limit is exp(lclm) and upper limit is exp(uclm).

- CI for ratios of AUC and Cmax between visits
First log-transformed for each value, i.e. log(aval) = log(aval).

```sql
ods output conlimits=<out>
proc ttest data=<data> alpha=0.10;
   paired <lnAval_week6> * <lnAval_day1>
run;
```

6. STATISTICAL METHODS

6.1. Disposition of Subjects

The number and percentage of subjects screened, failed screening along with the primary reason for screen failure will be summarized for subjects in the enrolled population. The enrollment status will also be listed.

The number and percentage of subjects in each population and the reasons for exclusion from the PPP will be summarized for subjects in the enrolled population. The exclusion reason will also be listed.

The number and percentage of subjects enrolled from each site will be summarized and listed for subjects in the enrolled, safety and per protocol population.

The number and percentage of subjects under study treatment, discontinued from study treatment and the primary reason for discontinuation from study treatment will be summarized in the safety population. The corresponding listing will be provided.

For the follow up phase (safety and/or routine follow up phases), the number and percentage of patients entered the follow-up phase will be summarized.

6.2. Demographic and Baseline Disease Characteristics

Demographic and baseline variables will be summarized and listed for all subjects in the safety population and PK population.

The duration of PTCL is from the initial diagnosis date or first prior treatment date of PTCL, whichever occurs earlier, to the date of inform consent signed off. If initial diagnosis date does not have complete information of day, month, and year, it will be imputed as the rule defined in section 5.2.

Continuous variables include age, height, weight, BMI (weight (kg)/height (m)^2), BSA, duration of PTCL and number of regimen of prior systemic therapy (including Chemotherapy, Autologous stem cell transplant).

Categorical variables include age group, gender, race, ethnicity, subtype of PTCL both from investigator and central review, ECOG performance status, documented progressive disease on prior treatment of PTCL, prior treatment of PTCL, best response to any of prior treatment of PTCL and last response to all the prior treatments of PTCL.
6.3. Protocol Deviations

The following protocol deviations may exclude a subject from the PPP:

- Failure to comply with the major inclusion/exclusion criteria, e.g., not meeting the Inclusion Criterion #1 the histopathological subtype confirmed by central pathology review
- Being non-compliant with study treatments
  - Without completing of a minimal 3 doses of exposure to the treatment regimen of one treatment cycle, except discontinuation due to toxicity and disease progression
- Taking any prohibited concomitant therapies

Major protocol deviations will be agreed at the data review meeting prior to database lock. Major protocol deviations will be summarized and all the protocol deviations will be listed.

6.4. Medical/Surgical History (Other than PTCL)

Medical/surgical history (other than PTCL) will be summarized and listed by System Organ Class (SOC) and Preferred Term (PT) in the safety population.

6.5. Concomitant Medication

Concomitant medication will be summarized and listed by coded term using WHO Drug Dictionary in the safety population.

The number and percentage of subjects taking concomitant medications will be summarized by ATC anatomical class (ATC level 1), pharmacological class (ATC level 2), pharmacological sub-class (ATC level 3) and coded term for subjects in the safety population.

6.6. Exposure

6.6.1. IMP Analyses

The following variables will be defined to assess exposure to study treatment:

- Number of infusions
- Duration of treatment (weeks): First calculate [(Date of last dose - date of first dose) + 7] ÷ 7 per subject per cycle. Then sum all the cycle durations for each subject.
- Cumulative dose (mg/m\(^2\)) = Sum of all total doses administered (mg/m\(^2\))
- Dose intensity (mg/m\(^2\)/week) = Cumulative dose (mg/m\(^2\)) ÷ Duration of treatment (week)
- Relative dose intensity (%) = Dose intensity ÷ Planned weekly dose intensity x 100, whereas planned weekly dose intensity (mg/m\(^2\)/week) = 30 mg/m\(^2\)/week
All these variables will be summarized as continuous data. Additionally, the relative dose intensity will be categorically summarized (i.e., number and percentage of subjects with relative dose intensity of <60%, 60-<80%, 80-<90%, 90-<110%, 110-<120%, >=120%).

Moreover, the number and percentage of subjects with any dose reduction, temporarily interrupted, permanently discontinued, not administered and corresponding reason will be presented.

The number and percentage of total cycles subjects received as well as the maximum cycle number will be presented.

Listing of exposure will also be provided.

6.6.2. **Vitamin Supplementation Analyses**

Vitamin B12 administration will be listed by subject.

Compliance of folic acid will be summarized by cycle. The compliance will be calculated as (duration per cycle – number of days with dose skipped per cycle)/ duration per cycle. Also the listing will be provided.

6.7. **Safety Analyses**

Safety data that will be evaluated includes adverse events (AEs), serious adverse events (SAEs), laboratory assessment, vital signs, ECG and other tests. Safety data will be summarized for subjects in the safety population.

6.7.1. **Adverse Events (AEs) and Serious Adverse Events (SAEs)**

AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system to give a System Organ Class (SOC) and Preferred Term (PT) for each event. Events will also be graded for severity according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.

Only TEAEs (treatment emergent adverse event) will be summarized. A treatment emergent AE is defined as any AE with an onset date on or after the first dose of IMP if the AE is absent before the first dose of IMP, or worsened after the first dose of IMP. This will also include AEIs with an onset date up to and including 30 days after the last dose of IMP. In addition, this will include AEIs with an onset date after 30 days considered as related to IMP by the investigator.

An overview summary table of TEAEs including treatment related TEAEs, CTCAE grade>=3 TEAEs, treatment related CTCAE grade>=3 TEAEs, treatment emergent SAEs, treatment related and emergent SAEs, significant TEAEs (leading to death, requiring treatment given, leading to IMP dose decreased, withheld transiently, discontinuation) will be provided.
In general, the number and percentage of subjects reporting any TEAEs will be summarized by the preferred term nested within the SOCs. Although a MedDRA term may be reported more than once for a subject, that subject will be counted only once in the incidence count for that MedDRA term.

A summary of TEAEs by SOC, PT and maximum CTCAE grade will also be provided. In addition, the number of reported TEAEs will be summarized.

Also, a listing of AEs will be prepared, including AE start/end date, CTCAE grade, relationship to IMP, serious or not, action taken to IMP and AE outcome.

TEAE leading to withdrawal and Treatment emergent SAEs would be tabulated.

Moreover, in order to ensure that the true occurrence rate of AEs is not obscured in cases where certain AEs are reported with similar preferred terms, certain AE terms will be grouped used the MedDRA version 18.0. For this presentation, certain similar preferred terms will be identified, grouped, and coded to a single preferred term, which are deemed to represent the same conditions from a medical perspective, in order to present the event in a uniform manner. The grouping of AE terms will be as follows:

- Liver Function Test Abnormal (including Alanine Aminotransferase Increased, Alanine Aminotransferase, Aspartate Aminotransferase, Aspartate Aminotransferase Increased, and Transaminases Increased)
- Mucosal Inflammation (including Stomatitis, Stomatitis Haemorrhagic, Anal Inflammation, Vaginal Inflammation, Proctitis, Oesophagitis, Mouth Ulceration, Oral Mucosal Erythema, Pharyngeal Inflammation, Pharyngitis, Gingivitis, and Balanoposthitis)
- Thrombocytopenia (including Platelet Count Decreased)
- Oedema (including Oedema Peripheral)
- Dry Mouth (including Lip Dry and Dry Throat)
- Dyspepsia (including Gastritis and Gastrooesophageal Reflux Disease)
- Odynophagia (including Oesophageal Pain)
- Pruritus (including Pruritus Generalized)
- Anemia (including Hemoglobin Decreased)
- Hypokalemia (including Blood Potassium Decreased)
- Neutropenia (including Neutrophil Count Decreased)
- Leukopenia (including White Blood Cell Count Decreased)
- Lymphopenia (including Lymphocyte count decreased)

Summary of the incidence of all TEAEs, treatment-related, CTCAE grade>=3 AEs and SAEs grouped by the similar preferred terms as above will also be presented.

6.7.2. Laboratory Assessment

Clinical laboratory data to be summarized includes haematology, blood chemistry, and urinalysis.
Clinical laboratory results recorded at each visit and change from baseline to each visit will be summarized as continuous data for each parameter.

Normal and abnormalities (with/without clinical significance) in each laboratory parameter will be summarized by cycle and listed.

Shift tables of normal and abnormalities from baseline to the post baseline will be generated.

Scatter plots will be produced for each laboratory parameter comparing baseline and end of study values. In addition, clinically laboratory parameters will be plotted over time using a box and whisker plot.

Each parameter will be assigned an LNH classification according to whether the value is lower than (L), within (N) or higher than (H) the reference range for that parameter. Results will be summarized using shift tables to evaluate categorical changes from baseline to end of study with respect to reference range values (lower than, within, higher than).

Clinical laboratory values after first dose of IMP will be evaluated for markedly abnormal values. Laboratory ranges used to identify markedly abnormal laboratory values will be defined in table 3. The number and percentage of subjects reporting markedly abnormal values will be summarized for each parameter. Each subject can be counted once in the parameter high and the parameter low categories, as applicable.

### Table 3 Laboratory Ranges Used to Identify Markedly Abnormal Laboratory Values

<table>
<thead>
<tr>
<th>Units</th>
<th>Laboratory Parameter</th>
<th>Lower Limit</th>
<th>Upper Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Haematology</strong></td>
<td>Haemoglobin</td>
<td>&lt;10 g/dL (100 g/L) or &lt;6.2 mmol/L</td>
<td>——</td>
</tr>
<tr>
<td></td>
<td>Platelets</td>
<td>&lt;750.0 × 10⁹/L or &lt;75000/mm³</td>
<td>——</td>
</tr>
<tr>
<td></td>
<td>Leukocytes</td>
<td>&lt;3.0 × 10⁹/L or &lt;3000/mm³</td>
<td>——</td>
</tr>
<tr>
<td></td>
<td>Lymphocytes</td>
<td>&lt;1.0 × 10⁹/L or &lt;1000/mm³</td>
<td>——</td>
</tr>
<tr>
<td></td>
<td>Neutrophils</td>
<td>&lt;1.5 × 10⁹/L or &lt;1500/mm³</td>
<td>——</td>
</tr>
<tr>
<td><strong>Clinical Chemistry</strong></td>
<td>Electrolytes</td>
<td>Sodium &lt; LLN</td>
<td>&gt;150 mmol/L</td>
</tr>
<tr>
<td></td>
<td>Potassium</td>
<td>&lt; LLN</td>
<td>&gt;5.5 mmol/L</td>
</tr>
<tr>
<td></td>
<td>Bicarbonate (HCO₃⁻)</td>
<td>≤15 mEq/dL or ≤15 mmol/L</td>
<td>——</td>
</tr>
<tr>
<td><strong>Liver Function Tests</strong></td>
<td>Alkaline phosphatase</td>
<td>——</td>
<td>&gt;3 × ULN</td>
</tr>
<tr>
<td></td>
<td>AST</td>
<td>——</td>
<td>&gt;3 × ULN</td>
</tr>
<tr>
<td></td>
<td>ALT</td>
<td>——</td>
<td>&gt;3 × ULN</td>
</tr>
<tr>
<td></td>
<td>GGT (GGTP)</td>
<td>——</td>
<td>&gt;3 × ULN</td>
</tr>
<tr>
<td></td>
<td>Total bilirubin</td>
<td>——</td>
<td>&gt;1.5 × ULN</td>
</tr>
<tr>
<td><strong>Renal Function Tests</strong></td>
<td>Creatinine</td>
<td>——</td>
<td>&gt;1.5 × ULN</td>
</tr>
<tr>
<td><strong>Other Chemistry</strong></td>
<td></td>
<td>——</td>
<td>——</td>
</tr>
</tbody>
</table>
6.7.3. Vital Signs

Vital sign parameters to be summarized include systolic blood pressure, diastolic blood pressure, pulse rate, respiration rate, and axillary temperature.

Vital sign results recorded at each visit and change from baseline to each visit will be summarized as continuous data for each parameter.

Scatter plots will be produced for each vital sign parameter comparing baseline and end of study values. In addition, vital signs will be plotted over time using a box and whisker plot.

Vital sign results for each parameter will be assigned an LNH classification according to whether the value is lower than (L), within (N) or higher than (H) the reference range for that parameter. Vital sign results will be summarized using shift tables to evaluate categorical changes from baseline to end of study with respect to reference range values (lower than, within, higher than). The range will be defined in table 4.

Table 4 Reference Range for Vital Sign Parameter

<table>
<thead>
<tr>
<th>Vital Sign Parameter</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic blood pressure</td>
<td>90-140 mmHg</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>60-90 mmHg</td>
</tr>
<tr>
<td>Pulse rate</td>
<td>60-100 bpm</td>
</tr>
<tr>
<td>Axillary Temperature</td>
<td>≤ 12-20 breaths per minute</td>
</tr>
<tr>
<td></td>
<td>≤ 37 °C</td>
</tr>
</tbody>
</table>

Vital sign values after first dose of IMP will be evaluated for clinically notable abnormalities. Criteria used to identify clinically notable vital sign abnormalities will be defined in table 5. The number and percentage of subjects reporting clinically notable abnormalities will be summarized for each parameter. Each subject can be counted once in the parameter high and the parameter low categories, as applicable.

Table 5 Criteria Used to Identify Clinically Notable Vital Sign Abnormalities

<table>
<thead>
<tr>
<th>Vital Sign Parameter</th>
<th>Value</th>
<th>Change From Baseline a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic blood pressure</td>
<td>≥ 180 mmHg</td>
<td>Increase of ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>≤ 90 mmHg</td>
<td>Decrease of ≥ 20 mmHg</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>≥ 105 mmHg</td>
<td>Increase of ≥ 15 mmHg</td>
</tr>
<tr>
<td></td>
<td>≤ 50 mmHg</td>
<td>Decrease of ≥ 15 mmHg</td>
</tr>
<tr>
<td>Pulse rate</td>
<td>≥ 120 bpm</td>
<td>Increase of ≥ 15 bpm</td>
</tr>
</tbody>
</table>
≤ 50 bpm | Decrease of ≥ 15 bpm
---|---
Respiration rate | < 8 breaths/minute | -
| ≥ 24 breaths/minute | -

*a Both value and change from baseline criteria must be met to qualify as a clinically notable vital sign abnormality.

### 6.7.4. ECG

Clinically significant ECG findings as determined by the Investigator will be summarized and listed.

### 6.7.5. Other Tests

Physical examination will be summarized by normal/abnormal and listed by visit.

PTCL related symptoms and results of bone marrow examination will be listed.

### 6.8. Efficacy Analyses

#### 6.8.1. Primary Efficacy Variable

The primary endpoint is the objective response rate (ORR) by International Working Criteria defined as the proportion of subjects with CR, CRu or PR as Best Overall Response (BOR). The objective response rate will be tested using the exact binomial test for single proportion at two-sided significance level of 5%. The hypotheses under test will be H0: ORR=15% vs. H1: ORR≠15%.

The primary analysis will be based on the independent review data using the safety population. An additional analysis based on the investigator assessment data will be performed. All analyses will be repeated using the per-protocol population.

Also present number of subjects achieved response by site.

#### 6.8.2. Secondary Efficacy Variables

- **Duration of Response (DOR)**

  Duration of response will be derived based on responders. Duration of response will be measured from first response date, i.e. first achieved CR/CRu/PR, to the date of disease progression or death, whatever comes first. The subject will be considered as event if the response is PD or the subject died after achieving CR/CRu/PR, and the event end date will be the PD date or death date, whatever comes first. The duration is calculated as (minimum (first PD or death date) – first response date + 1)/30.4375.

  If the subject receives subsequent therapy, including transplant, before PD or death, the subject will be censored at that time. The subject who withdraw consent to participate in the study prior to progression will be censored at the date of their last evaluable assessment of response. The subject who withdraw from treatment prior to progression
without withdrawing consent will be followed for disease status whenever possible. Otherwise the subject will be censored at the date of last tumor assessment date.

Duration of complete response will also be calculated. The algorithm is the same of DOR but change endpoint from CR/CRu/PR to CR/CRu.

- **Time to Response (TTR)**

  Time to first response will be derived based on responders. Time to first response will be measured from first treatment date to the first date of documented response. If the response is CR, CRu or PR, then the subject will be considered as event and event end date will be the earliest date of archived any of CR, CRu or PR. The duration is calculated as (minimum (CR date, CRu date, PR date) – first treatment date + 1)/30.4375.

  Time to best response will also be calculated. Time to best response will be measured from first treatment date to the date of documented best response (CR is better than CRu, CRu is better than PR). The event rule and censor rule is the same as time to first response.

- **Progression Free Survival (PFS)**

  PFS will be measured from first treatment date until PD or death, whatever comes first. The subject will be considered as event if the response is PD or the subject died, and the event end date will be the PD date or death date, whatever comes first. The duration is calculated as (minimum (first PD or death date) – first treatment date + 1)/30.4375.

  If the subject receives subsequent therapy, including transplant, before PD or death, the subject will be censored at that time. The subject who withdraw consent to participate in the study prior to progression will be censored at the date of their last evaluable assessment of response. The subject who withdraw from treatment prior to progression without withdrawing consent will be followed for disease status whenever possible. Otherwise the subject will be censored at the date of last tumor assessment date. If the subject has no assessment, then the subject will be censored at first treatment date.

- **Overall Survival (OS)**

  OS will be measured from first treatment date until death. The subject will be considered as event if the subject died, and the event end date will be the death date. The duration is calculated as (death date) – first treatment date + 1)/30.4375.

  The subject who withdraw consent to participate in the study, including consent to be followed, will be censored on the date of withdrawal. The subject who withdraw from treatment without withdrawing consent will be followed for survival status whenever possible. Otherwise the subject will be censored at the date of last contact date.

  Time to response endpoints will be summarized as continuous variable using descriptive statistics. Also will be categorized by response occurred cycle.
Other secondary time-to-event endpoints (e.g. duration of response, PFS, and OS) will be presented using Kaplan-Meier curves (product limit estimates) together with a summary of associated statistics (e.g. median survival time, first and third quartiles, survival rates including the corresponding two-sided confidence intervals [CIs]).

Response will be assessed by independent central review and by the treating investigator. Then for the secondary endpoints based on tumor assessments (e.g. duration of response, time to response and PFS), they will be analysed twice, once using the independent review data and once using the investigator assessment data.

Shift table will be presented to compare response between investigator assessment and central review assessment.

The secondary analyses will be performed using the safety population and repeated using the per-protocol population.

Listing of tumor assessment will be presented with independent review data investigator assessment data.

6.8.3. Discordance between Independent Central Review and Investigator Assessment

The early discrepancy rate and late discrepancy rate as defined below will be summarized. The agreement between independent central review and investigator is represented in a tabular form (table 6) below.

<table>
<thead>
<tr>
<th></th>
<th>Independent Central Review</th>
<th>No PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigator PD</td>
<td>a = a1 + a2 + a3</td>
<td>b</td>
</tr>
<tr>
<td>No PD</td>
<td>c</td>
<td>d</td>
</tr>
</tbody>
</table>

a1: number of agreements on timing and occurrence of PD.
a2: number of times investigator declares PD later than independent central review.
a3: number of times investigator declares PD earlier than independent central review.

The early discrepancy rate (EDR) is defined as

$$ EDR = \frac{b + a3}{a + b} $$

The EDR represents the positive predictive value of investigator assessment and quantifies the frequency with which the investigator declares progression early relative to independent central review as a proportion of the total number of investigator assessed PD’s.

The late discrepancy rate (LDR) is defined as

$$ LDR = \frac{c + a2}{b + c + a2 + a3} $$
6.9. Subgroup Analyses

For the objective response rate, subgroup analyses will be performed. If any category is less than 5 subjects, then only generate number of responder and response rate, i.e. no need to create CI and p-value.

The following subgroups will be examined.

- Age group (<55, 55-<65 or >=65)
- Gender (male or female)
- PTCL subtype from Investigator
  - PTCL not otherwise specified (NOS)
  - Angioimmunoblastic T-cell lymphoma
  - Anaplastic large cell lymphoma, ALK+
  - Anaplastic large cell lymphoma, ALK-
  - Extranodal NK/T-cell lymphoma - nasal type
  - Enteropathy-associated T cell lymphoma
  - Hepatosplenic T-cell lymphoma
  - Subcutaneous panniculitis-like T-cell lymphoma
  - Adult T-cell lymphoma/leukemia (human T-cell leukemia virus[HTLV] 1+)
  - Aggressive NK-cell leukemia
  - Transformed mycosis fungoides
  - Other
- Best response to any of prior treatment of PTCL (responder (CR + CRu + PR) or non-responder)
- Last response to all the prior treatments of PTCL (responder (CR + CRu + PR) or non-responder)
- Number of regimen of Prior Systemic Therapy (1, 2, 3 or >=4)
- Time from most recent therapy (<3 months or >=3 months)
- LDH level at baseline (above normal or normal/low)

6.10. Pharmacokinetic Analyses

The PK profile of R-pralatrexate and S-pralatrexate will be determined in 15 subjects at pre-selected sites.

The collection times for full pralatrexate PK are as follows:
- Cycle 1, dose 1: Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection.
- Cycle 1, doses 2 – 5: Pre-injection
- Cycle 1, dose 6: Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection.

6.10.1. Plasma Concentration

Plasma concentration data will be listed by analyte (R-pralatrexate and S-pralatrexate) for subjects in the pharmacokinetic population.

Plasma concentrations for each analyte will be summarized descriptively by nominal time-point for subjects in the pharmacokinetic population as continuous data. All values below the quantifiable limit will be set to 0 for descriptive summary statistics. Individual and mean (SD) plasma concentration profiles for each analyte for subjects in the pharmacokinetic population will be presented graphically in a linear and log linear scale.

6.10.2. Pharmacokinetic Parameters

Noncompartmental method (Phoenix WinNonlin, Version 6.3 or higher version, Certara, Princeton, USA) will be used to derive pharmacokinetic parameters. The following pharmacokinetic parameters will be reported, AUCINF, AUCt, Cmax, CLss, LamdaZ, tmax, t1/2Z, Vdss, %AUCextra, ARAUC and ARCmax. PK parameters and relate CDISC standard terminology is listed in Table 7. Main formulas for calculation of PK parameters is listed in Table 8.

Table 7  Relate CDISC standard terminology of PK parameters

<table>
<thead>
<tr>
<th>PK parameters</th>
<th>CDISC standard terminology</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARAUC</td>
<td>ARAUC</td>
</tr>
<tr>
<td>ARCmax</td>
<td>ARCMAX</td>
</tr>
<tr>
<td>AUCINF</td>
<td>AUCIFO</td>
</tr>
<tr>
<td>AUCt</td>
<td>AUCLST</td>
</tr>
<tr>
<td>%AUCextra</td>
<td>AUCPEO</td>
</tr>
<tr>
<td>AUCtau</td>
<td>AUCTAU</td>
</tr>
<tr>
<td>CL(CLss)</td>
<td>CLO</td>
</tr>
<tr>
<td>Cmax</td>
<td>CMAX</td>
</tr>
<tr>
<td>R2ADJ</td>
<td>R Squared Adjusted</td>
</tr>
<tr>
<td>LamdaZ</td>
<td>LAMZ</td>
</tr>
<tr>
<td>t1/2Z</td>
<td>LAMZHL</td>
</tr>
<tr>
<td>tmax</td>
<td>TMAX</td>
</tr>
<tr>
<td>Vd(Vdss)</td>
<td>VZO</td>
</tr>
</tbody>
</table>

Table 8 Main formulas for calculation of PK parameters

<table>
<thead>
<tr>
<th>PK parameters</th>
<th>Unit</th>
<th>Formulas</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARAUC</td>
<td>Ratio</td>
<td>ARAUC=AUC\text{week6}/AUC\text{day1}</td>
</tr>
<tr>
<td>ARCmax</td>
<td>Ratio</td>
<td>ARCmax=Cmax\text{week6}/Cmax\text{day1}</td>
</tr>
<tr>
<td>AUCINF</td>
<td>h*ng/mL</td>
<td>Log linear trapezoid(Linear up log down) AUCINF=AUCt+Clast/ LamdaZ</td>
</tr>
</tbody>
</table>
Pharmacokinetic parameters will be listed by analyte for subjects in the PK population. Data excluded from the PK analysis will be flagged with an asterisk. If the %AUCextra is greater than 20% of AUCINF, this will be flagged in the listings. LambdaZ, t1/2 and AUCINF will not be included in statistical summaries or analysis if the adjusted R² in LambdaZ estimation is less than 0.8.

Pharmacokinetic parameters for each analyte will be summarised descriptively for subjects in the PK population, adjusting for dose where necessary. Descriptive statistics including mean, SD, coefficient of variation (CV), SE, number of subjects with available data (n), minimum, maximum, and median will be calculated for all pharmacokinetic parameters (except tmax) by analyte, study day, and the actual administered dose. Additionally, geometric means and geometric CV will be calculated for AUCt, AUCINF and Cmax. The algorithm is

\[
\text{Geometric means} = \exp\left(\frac{\log(y_1) + \ldots + \log(y_n)}{n}\right)
\]

\[
\text{Geometric SD} = \exp\left(\text{SD}(\log(y_1), \ldots, \log(y_n))\right)
\]

\[
\text{Geometric CV (\%)} = \left(\exp\left(\text{log}(\text{Geometric SD})^2\right) - 1\right)^{1/2} \times 100
\]

Tmax will be summarized by n, mean, minimum, maximum and median.

Log-transformed AUCt and Cmax at Day 1 and Week 6 will be used to calculate two-sided 90% confidence intervals for paired observations. Mean values and their associated confidence intervals will then be back transformed to provide point estimates and 90% confidence intervals for the ratios. Incomplete pairs will be excluded from the calculation. Only subjects who provided non-missing values for both periods, so that a non-missing day 1 to week 6 difference can be calculated, will be included.
7. ATTACHMENTS

1. Tables, listings and figures shell will be attached.

LIST OF TABLES

Table 1.1 Screen Failure Enrolled Population
Table 1.2 Analysis Populations Enrolled Population
Table 1.3 Disposition Enrolled Population
Table 1.4 Treatment Discontinuation Safety Population
Table 1.5 Site Enrolled Population
Table 2.1 Subject Demography Safety Population
Table 2.2 Subject Demography Pharmacokinetic Population
Table 2.3 Baseline Characteristics Safety Population
Table 2.4 Baseline Characteristics Pharmacokinetic Population
Table 3 Medical/Surgical History (Other than PTCL) By System Organ Class and Preferred Term Safety Population
Table 4 Concomitant Medication Safety Population
Table 4.1 Concomitant Medication by ATC Safety Population
Table 5.1 Study Treatment Exposure Safety Population
Table 5.2 Cycles Given Safety Population
Table 5.3 Treatment Adjustment Safety Population
Table 5.4 Compliance for Folic Acid Administration Safety Population
Table 6.1 Overview of All Treatment Emergent Adverse Events Safety Population
Table 6.1.1 Overview of Significant Treatment Emergent Adverse Events Safety Population
Table 6.2 Treatment Emergent Adverse Events By System Organ Class and Preferred Term Safety Population
Table 6.3 Serious Treatment Emergent Adverse Events By System Organ Class and Preferred Term Safety Population
Table 6.4 Treatment Related Treatment Emergent Adverse Events By System Organ Class and Preferred Term Safety Population
Table 6.5 Treatment Related Serious Treatment Emergent Adverse Events By System Organ Class and Preferred Term Safety Population
Table 6.6 CTCAE Grade >= 3 Treatment Emergent Adverse Events By System Organ Class and Preferred Term Safety Population

Table 6.7 Treatment Related CTCAE Grade >= 3 Treatment Emergent Adverse Events By System Organ Class and Preferred Term Safety Population

Table 6.8 Treatment Emergent Adverse Events Leading to IMP decreased By System Organ Class and Preferred Term Safety Population

Table 6.9 Treatment Emergent Adverse Events Leading to IMP Withheld transiently By System Organ Class and Preferred Term Safety Population

Table 6.10 Treatment Emergent Adverse Events Leading to IMP Withdraw Permanently By System Organ Class and Preferred Term Safety Population

Table 6.11 Treatment Emergent Adverse Events Leading to Death By System Organ Class and Preferred Term Safety Population

Table 6.12 Treatment Emergent Adverse Events by Maximum CTCAE Grade By System Organ Class and Preferred Term Safety Population

Table 6.13 Serious Treatment Emergent Adverse Events by Maximum CTCAE Grade By System Organ Class and Preferred Term Safety Population

Table 6.14 Treatment Related Treatment Emergent Adverse Events by Maximum CTCAE Grade By System Organ Class and Preferred Term Safety Population

Table 6.14.1 Grouped Treatment Emergent Adverse Events by Maximum CTCAE Grade By System Organ Class and Preferred Term Safety Population

Table 6.15 Grouped Treatment Emergent Adverse Events By Similar Preferred Term Safety Population

Table 6.16 Grouped Serious Treatment Emergent Adverse Events By Similar Preferred Term Safety Population

Table 6.17 Treatment Related Grouped Treatment Emergent Adverse Events By Similar Preferred Term Safety Population

Table 6.18 CTCAE Grade >= 3 Grouped Treatment Emergent Adverse Events By Similar Preferred Term Safety Population

Table 7.1 Continuous Laboratory Results Safety Population

Table 7.2 Categorical Laboratory Evaluations Safety Population

Table 7.3 Shift of Categorical Laboratory Evaluations by Clinically Significance Safety Population

Table 7.4 Shift of Categorical Laboratory Evaluations by Low/Within/High Classification Safety Population

Table 7.5 Markedly Abnormal Laboratory Evaluations Safety Population

Table 8.1 Continuous Vital Sign Results Safety Population

Table 8.2 Shift of Categorical Vital Sign by Low/Within/High Classification Safety Population
Table 8.3 Clinically Notable Vital Sign Safety Population
Table 9 Electrocardiogram Safety Population
Table 10 Physical Examination Safety Population
Table 11.1 Objective Response Rate Safety Population
Table 11.2 Objective Response Rate Per Protocol Population
Table 11.3 Best Overall Response Rate Safety Population
Table 11.4 Best Overall Response Rate Per Protocol Population
Table 11.5 Duration of Response Safety Population of Responder
Table 11.6 Duration of Response Per Protocol Population of Responder
Table 11.7 Time to First Response Safety Population of Responder
Table 11.8 Time to First Response Per Protocol Population of Responder
Table 11.7.1 Time to Best Response Safety Population Population of Responder
Table 11.8.1 Time to Best Response Per Protocol Population of Responder
Table 11.9 Progression Free Survival Safety Population
Table 11.10 Progression Free Survival Per Protocol Population
Table 11.11 Overall Survival Safety Population
Table 11.12 Overall Survival Per Protocol Population
Table 11.13 Duration of Complete Response Safety Population of Complete Responder
Table 11.14 Duration of Complete Response Per Protocol Population of Complete Responder
Table 11.15 Objective Response Rate by Site Safety Population
Table 11.16 Subsequent Treatment for PTCL Safety Population
Table 11.17 Shift of Best Response between Investigator Assessment and Central Review Assessment Safety Population
Table 11.18 Subgroup Analysis of Objective Response Rate by Subtype of PTCL from Investigator Safety Population
Table 11.18.1 Subgroup Analysis of Objective Response Rate by Subtype of PTCL from Central review Safety Population
Table 11.19 Subgroup Analysis of Objective Response Rate by Best Response to Any of Prior Treatment of PTCL Safety Population
Table 11.20 Subgroup Analysis of Objective Response Rate by Number of Regimen of Prior Systemic Therapy Safety Population
Table 11.21 Subgroup Analysis of Objective Response Rate by Age Group Safety Population
Table 11.22 Subgroup Analysis of Objective Response Rate by Gender Safety Population
Table 11.22.1 Subgroup Analysis of Objective Response Rate by Last response to all the prior treatments of PTCL Safety Population

Table 11.22.2 Subgroup Analysis of Objective Response Rate by Time from most recent therapy Safety Population

Table 11.22.3 Subgroup Analysis of Objective Response Rate by LDH level at baseline Safety Population

Table 11.23 Discordance between Investigator Assessment and Central Review Assessment Safety Population

Table 12.1 Summary of Plasma Concentration by Analyte and Time Pharmacokinetic Population

Table 12.2 Summary of Plasma Concentration by Analyte and Time Sensitivity Analysis

Table 12.3 Summary of Pharmacokinetic Parameters (except tmax) by Analyte Pharmacokinetic Population

Table 12.4 Summary of Pharmacokinetic Parameters (except tmax) by Analyte Sensitivity Analysis

Table 12.5 Summary of Pharmacokinetic Parameters (tmax) by Analyte Pharmacokinetic Population

Table 12.6 Summary of Pharmacokinetic Parameters (tmax) by Analyte Sensitivity Analysis

Table 12.7 Summary of Pharmacokinetic Parameters (AUC and Cmax) by Analyte Pharmacokinetic Population

Table 12.8 Summary of Pharmacokinetic Parameters (AUC and Cmax) by Analyte Sensitivity Analysis

Table 12.9 Comparison of Pharmacokinetic Parameters (AUCLST and Cmax) between different visits by Analyte Pharmacokinetic Population

Table 12.10 Comparison of Pharmacokinetic Parameters (AUCLST and Cmax) between different visits by Analyte Sensitivity Analysis

LIST OF LISTINGS

Listing 1.1 Screen Failure Enrolled Population

Listing 1.2 Population Enrolled Population

Listing 1.3 Protocol Deviations Enrolled Population

Listing 2 Treatment Completion Safety Population

Listing 3 Subject Demographics and Baseline Characteristics Safety Population

Listing 4 History and Prior Treatment of PTCL Safety Population

Listing 5 Medical/Surgical History (Other than PTCL) Safety Population

Listing 6 Concomitant Medication Safety Population
Listing 7.1 Exposure Safety Population
Listing 7.2 Vitamin B12 Administration Safety Population
Listing 7.3 Folic Acid Administration Safety Population
Listing 8 Adverse Event Safety Population
Listing 8.1 Treatment Emergent Adverse Event Leading to IMP Withdraw Permanently Safety Population
Listing 8.2 Serious Treatment Emergent Adverse Events Safety Population
Listing 8.3 Significant Treatment Emergent Adverse Events Safety Population
Listing 8.4 Death Safety Population
Listing 9.1 Laboratory Evaluations (Other than LDH) Safety Population
Listing 9.2 Laboratory Evaluations (LDH) Safety Population
Listing 10 Vital Sign Safety Population
Listing 11 Electrocardiogram Safety Population
Listing 12 Physical Examination Safety Population
Listing 13 PTCL Related Symptoms Safety Population
Listing 14 Bone Marrow Examination Safety Population
Listing 15 Cutaneous Lesions Measurement Safety Population
Listing 16 Target Lesion Safety Population
Listing 17 Non-target Lesion Safety Population
Listing 18 New Lesion Safety Population
Listing 19 Overall Response Assessed by Investigator and Central Review Safety Population
Listing 20 Progress Disease Safety Population
Listing 21 Component of Response Assessment Safety Population
Listing 22 Efficacy Time to Event Variables Safety Population
Listing 23 Listing of Plasma Concentration Pharmacokinetic Population
Listing 24 Listing of Pharmacokinetic Parameters Pharmacokinetic Population

LIST OF FIGURES

Figure 1 Scatter Plot of Laboratory Evaluations in Baseline and End of Study Safety Population
Figure 2 Boxplot of Laboratory Evaluations Safety Population
Figure 3 Scatter Plot of Vital Sign in Baseline and End of Study Safety Population
Figure 4 Boxplot of Vital Sign Safety Population
Figure 5 Kaplan-Meier Graph of Duration of Response Safety Population
Figure 6 Kaplan-Meier Graph of Duration of Complete Response Safety Population
Figure 7 Kaplan-Meier Graph of Progression Free Survival Safety Population
Figure 8 Kaplan-Meier Graph of Overall Survival Safety Population
Figure 9 Individual Plasma Concentration Plot (Linear and Semi-log) Pharmacokinetic Population
Figure 10 Mean (SD) Plasma Concentration Plot (Linear and Semi-log) Pharmacokinetic Population
Figure 11 Mean (SD) Plasma Concentration Plot (Linear and Semi-log) Sensitivity Analysis